← Leaderboards
Keith Kaye
University Of Michigan At Ann Arbor
$11,130,173
Attributed
$11,130,173
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.5M · FY2017–19$10M$7.5M$5M$2.5M$0
'17
'18
'19
Funding mix
By agency
NIH$11,130,173 · 1
By mechanism
N01$11,130,173 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Lona Mody$10,883,116
- Jacques Eduardo Nor$18,171,241
- Chelsie Elizabeth Armbruster$5,621,521
- Susan Marie Ferguson$10,423,131
- Jeffrey S Chamberlain$54,800,495
Others in their field
Other Emerging Leaders on “Antibiotic Resistance”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$25,064,821
- Bruce Blough · Research Triangle Institute$19,880,022
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Terry Roemer · Prokaryotics, Inc.$13,917,276
Research focus
Antibiotic ResistanceAntimicrobial ResistanceClinical TrialsDrug ExposureGram-Negative BacteriaMultidrug-Resistant AcinetobacterProbabilityRegimenSafety TestingTherapeutic EffectivenessTherapeutic Evaluation
Grant awards (3)
TARGETED CLINICAL TRIALS TO REDUCE THE RISK OF ANTIMICROBIAL RESISTANCE$1,432,000
N01 · FY2019 · AI · contact PI
TARGETED CLINICAL TRIALS TO REDUCE THE RISK OF ANTIMICROBIAL RESISTANCE$1,188,983
N01 · FY2018 · AI · contact PI
TARGETED CLINICAL TRIALS TO REDUCE THE RISK OF ANTIMICROBIAL RESISTANCE$8,509,190
N01 · FY2017 · AI · contact PI